EUCTR2010-019518-25-IT进行中（未招募）不适用
(Maraviroc ENHancement of Immunological Response): A pilot study of maraviroc as an add-on in patients with reduced CD4 cell count despite full viral suppression - MENHIR
AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)0 个研究点开始时间: 2010年5月13日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •i. Age > 18 years
- •ii. Informed consent signed (add. 1)
- •iii. Patients with a reduced CD4 cell count (<250 cells/mmc) response to HAART despite full viral suppression (HIV-RNA <50 copies/ml) for at least 6 months.
- •iv. Stable HAART for least 6 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •i. Childbearing or breastfeeding. Women of childbearing potential will be asked to adopt effective contraceptive methods or behaviours
- •ii. Any ongoing grade 4 (WHO) AE or laboratory abnormality.
- •iii. Allergy/intolerance to the study drug
- •iv. Treatment with immunomodulatory agents
- •v. Treatment with steroids
- •vi. Radiotherapy or chemotherapy
- •vii. HAART consisting of a combination of tenofovir and didanosine
- •viii. Autoimmune disorder or chronic inflammatory disease
研究者
相似试验
进行中（未招募）
不适用
se of Maraviroc (MVC) in immunogical non-responder HIV-1-infected patients. - NDHIV-1-infected HAART-treated patients that reached a virologic suppression without a reconstitution of their immune system.MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2008-002661-30-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
进行中（未招募）
不适用
Maraviroc Immune Recovery Study (MIRS):A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recovery - MIRSEUCTR2008-003635-20-NLniversitair Medisch Centrum Utrecht
招募中
不适用
MOODSTRATIFICATION IMMUNOSTRATAPremature immune ageing to predict the effect of physical training intervention, in mood disordersF32F33F31Depressive episodeRecurrent depressive disorderBipolar affective disorderDRKS00022887niversitätsklinikum Münster500
Enrolling By Invitation
Unknown
Improvement of immune status, parasympathetic response, body composition and fascial elasticity in stressed persons by applying cryotherapy in a cold chamber at minus 90 degreesStimulation of the immune system, reduction of plasma ACE2, increase of the parasympathetic nervous system and fascia flexibility through cryotherapy at minus 90 degrees.DRKS00031033Stiftung Immunweltmeister e. V.20
招募中
2 期
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS studyBlood - Haematological diseasesMultiple MyelomaACTRN12621001037897Australasian Myeloma Research Consortium50